{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    13,
    14,
    15,
    16,
    17,
    21,
    22,
    23,
    24
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by radiographic progression-free survival (rPFS) based on central review",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective - OS",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by overall survival (OS)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective - SSE",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by time to first Symptomatic Skeletal Event (SSE)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - Castration Resistance",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by time to castration resistance",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - QoL",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by Quality of Life (QoL) (as measured by Quality of Life Prostate-specific Questionnaire [QLQ-PR25] / Functional Assessment of Cancer Therapy-Prostate [FACT-P] and EuroQol Group-5 Dimension-5 Level Instrument [EQ-5D-5L])",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective - Antineoplastic Therapy",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by time to start of new antineoplastic therapy",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Objective - PSA Progression",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by time to prostate-specific antigen (PSA) progression",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Objective - PSA Undetectable",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by PSA undetectable rate (< 0.2 ng/mL)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Secondary Objective - ORR",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by objective response rate (ORR)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Secondary Objective - Pain",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by worsening of pain (as measured by Brief Pain Inventory-Short Form [BPI-SF])",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Safety Objective",
        "text": "To determine the safety of enzalutamide plus ADT as compared to placebo plus ADT",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12",
          "ep_13",
          "ep_14",
          "ep_15",
          "ep_16"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Exploratory Objective",
        "text": "To determine gene mutations potentially related to resistance of enzalutamide plus ADT as assessed by DNA mutation testing in plasma",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_17"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "rPFS",
        "text": "rPFS (based on central review)",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "OS",
        "text": "OS",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Time to first SSE",
        "text": "Time to first SSE",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Time to castration resistance",
        "text": "Time to castration resistance",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Time to deterioration of QoL",
        "text": "Time to deterioration of QoL",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_6",
        "name": "Time to deterioration in urinary symptoms",
        "text": "Time to deterioration in urinary symptoms",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_7",
        "name": "Time to initiation of new antineoplastic therapy",
        "text": "Time to initiation of new antineoplastic therapy",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Time to PSA progression",
        "text": "Time to PSA progression (≥ 2 ng/mL) (Prostate Cancer Clinical Trials Working Group 2 criteria)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "PSA undetectable rate",
        "text": "PSA undetectable rate (< 0.2 ng/mL)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "ORR",
        "text": "ORR",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Time to pain progression",
        "text": "Time to pain progression",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Adverse Events",
        "text": "Nature, frequency and severity of adverse events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_13",
        "name": "Safety laboratory tests",
        "text": "Safety laboratory tests: biochemistry and hematology",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_14",
        "name": "Physical examination",
        "text": "Physical examination",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_15",
        "name": "ECG",
        "text": "ECG",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_16",
        "name": "Vital signs",
        "text": "Vital signs (blood pressure, pulse and temperature)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_17",
        "name": "Mutation status",
        "text": "Mutation status in plasma of genes potentially related to resistance of enzalutamide plus ADT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - rPFS",
        "populationSummary": "Adult patients with metastatic hormone sensitive prostate cancer (mHSPC) (ITT population) Summary measure: Hazard ratio from stratified Cox Regression.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Death",
            "text": "Death from any cause within 24 weeks after study drug discontinuation",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Treatment discontinuation without progression",
            "text": "Subject discontinues study treatment for reasons other than radiographic progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Initiation of new antineoplastic therapy",
            "text": "Starting an investigational agent or new therapy for treatment of prostate cancer prior to radiographic progression",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Enzalutamide 160 mg daily plus ADT vs Placebo plus ADT",
        "analysisPopulation": "Adult patients with metastatic hormone sensitive prostate cancer (mHSPC) (ITT population)",
        "variableOfInterest": "Radiographic progression-free survival (rPFS) based on central review",
        "summaryMeasure": "Hazard ratio from stratified Cox Regression"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand - OS",
        "populationSummary": "Adult patients with metastatic hormone sensitive prostate cancer (mHSPC) (ITT population) Summary measure: Hazard ratio from stratified Cox Regression.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment switching/crossover",
            "text": "Placebo subjects receiving enzalutamide after progression or study unblinding",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Enzalutamide 160 mg daily plus ADT vs Placebo plus ADT",
        "analysisPopulation": "Adult patients with metastatic hormone sensitive prostate cancer (mHSPC) (ITT population)",
        "variableOfInterest": "Overall survival (OS)",
        "summaryMeasure": "Hazard ratio from stratified Cox Regression"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - PSA Undetectable Rate",
        "populationSummary": "Adult patients with mHSPC and detectable PSA (≥ 0.2 ng/mL) at baseline Summary measure: Odds ratio using stratified Cochran-Mantel-Haenszel score test.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_9",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug prior to achieving undetectable PSA",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Enzalutamide 160 mg daily plus ADT vs Placebo plus ADT",
        "analysisPopulation": "Adult patients with mHSPC and detectable PSA (≥ 0.2 ng/mL) at baseline",
        "variableOfInterest": "PSA undetectable rate (< 0.2 ng/mL)",
        "summaryMeasure": "Odds ratio using stratified Cochran-Mantel-Haenszel score test"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 10,
      "exploratoryObjectives": 1,
      "totalEndpoints": 17,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Objective",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by radiographic progression-free survival (rPFS) based on central review",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary Objective - OS",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by overall survival (OS)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary Objective - SSE",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by time to first Symptomatic Skeletal Event (SSE)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Secondary Objective - Castration Resistance",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by time to castration resistance",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Secondary Objective - QoL",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by Quality of Life (QoL) (as measured by Quality of Life Prostate-specific Questionnaire [QLQ-PR25] / Functional Assessment of Cancer Therapy-Prostate [FACT-P] and EuroQol Group-5 Dimension-5 Level Instrument [EQ-5D-5L])",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Secondary Objective - Antineoplastic Therapy",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by time to start of new antineoplastic therapy",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Secondary Objective - PSA Progression",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by time to prostate-specific antigen (PSA) progression",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Secondary Objective - PSA Undetectable",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by PSA undetectable rate (< 0.2 ng/mL)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Secondary Objective - ORR",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by objective response rate (ORR)",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Secondary Objective - Pain",
        "text": "To determine the benefit of enzalutamide plus ADT as compared to placebo plus ADT as assessed by worsening of pain (as measured by Brief Pain Inventory-Short Form [BPI-SF])",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Safety Objective",
        "text": "To determine the safety of enzalutamide plus ADT as compared to placebo plus ADT",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12",
          "ep_13",
          "ep_14",
          "ep_15",
          "ep_16"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Exploratory Objective",
        "text": "To determine gene mutations potentially related to resistance of enzalutamide plus ADT as assessed by DNA mutation testing in plasma",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_17"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "rPFS",
        "text": "rPFS (based on central review)",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "OS",
        "text": "OS",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Time to first SSE",
        "text": "Time to first SSE",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Time to castration resistance",
        "text": "Time to castration resistance",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Time to deterioration of QoL",
        "text": "Time to deterioration of QoL",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_6",
        "name": "Time to deterioration in urinary symptoms",
        "text": "Time to deterioration in urinary symptoms",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      },
      {
        "id": "ep_7",
        "name": "Time to initiation of new antineoplastic therapy",
        "text": "Time to initiation of new antineoplastic therapy",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Time to PSA progression",
        "text": "Time to PSA progression (≥ 2 ng/mL) (Prostate Cancer Clinical Trials Working Group 2 criteria)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_9",
        "name": "PSA undetectable rate",
        "text": "PSA undetectable rate (< 0.2 ng/mL)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_10",
        "name": "ORR",
        "text": "ORR",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_11",
        "name": "Time to pain progression",
        "text": "Time to pain progression",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_12",
        "name": "Adverse Events",
        "text": "Nature, frequency and severity of adverse events",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_13",
        "name": "Safety laboratory tests",
        "text": "Safety laboratory tests: biochemistry and hematology",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_14",
        "name": "Physical examination",
        "text": "Physical examination",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_15",
        "name": "ECG",
        "text": "ECG",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_16",
        "name": "Vital signs",
        "text": "Vital signs (blood pressure, pulse and temperature)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_17",
        "name": "Mutation status",
        "text": "Mutation status in plasma of genes potentially related to resistance of enzalutamide plus ADT",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - rPFS",
        "populationSummary": "Adult patients with metastatic hormone sensitive prostate cancer (mHSPC) (ITT population) Summary measure: Hazard ratio from stratified Cox Regression.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Death",
            "text": "Death from any cause within 24 weeks after study drug discontinuation",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Treatment discontinuation without progression",
            "text": "Subject discontinues study treatment for reasons other than radiographic progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Initiation of new antineoplastic therapy",
            "text": "Starting an investigational agent or new therapy for treatment of prostate cancer prior to radiographic progression",
            "strategy": "Hypothetical",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Enzalutamide 160 mg daily plus ADT vs Placebo plus ADT",
        "analysisPopulation": "Adult patients with metastatic hormone sensitive prostate cancer (mHSPC) (ITT population)",
        "variableOfInterest": "Radiographic progression-free survival (rPFS) based on central review",
        "summaryMeasure": "Hazard ratio from stratified Cox Regression"
      },
      {
        "id": "est_2",
        "name": "Secondary Efficacy Estimand - OS",
        "populationSummary": "Adult patients with metastatic hormone sensitive prostate cancer (mHSPC) (ITT population) Summary measure: Hazard ratio from stratified Cox Regression.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment switching/crossover",
            "text": "Placebo subjects receiving enzalutamide after progression or study unblinding",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Enzalutamide 160 mg daily plus ADT vs Placebo plus ADT",
        "analysisPopulation": "Adult patients with metastatic hormone sensitive prostate cancer (mHSPC) (ITT population)",
        "variableOfInterest": "Overall survival (OS)",
        "summaryMeasure": "Hazard ratio from stratified Cox Regression"
      },
      {
        "id": "est_3",
        "name": "Secondary Efficacy Estimand - PSA Undetectable Rate",
        "populationSummary": "Adult patients with mHSPC and detectable PSA (≥ 0.2 ng/mL) at baseline Summary measure: Odds ratio using stratified Cochran-Mantel-Haenszel score test.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_9",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study drug prior to achieving undetectable PSA",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Enzalutamide 160 mg daily plus ADT vs Placebo plus ADT",
        "analysisPopulation": "Adult patients with mHSPC and detectable PSA (≥ 0.2 ng/mL) at baseline",
        "variableOfInterest": "PSA undetectable rate (< 0.2 ng/mL)",
        "summaryMeasure": "Odds ratio using stratified Cochran-Mantel-Haenszel score test"
      }
    ]
  }
}